LONDON (Alliance News) - ReNeuron Group PLC said Friday it has seen positive long term data from its phase I clinical trial of its CTX stem cell therapy for disabled stroke patients.
It plans to present the data at the 2015 European Stroke Organisation Conference in Glasgow Sunday.
The data is from a long-term follow up of all eleven patients treated in the study, and demonstrates that there were no cell-related or immunological adverse events reported in any of the patients. The only adverse events were related to the implantation procedure, or the patients underlying medical condition, ReNeuron said.
Improvements in neurological status and limb function were also observed within three months of treatment, and maintained throughout the long term follow up.
"The data confirm the good safety profile of our CTX stem cell treatment in this setting and it is particularly gratifying to see that the functional improvements previously observed in the patients against baseline measurements have been maintained in long term follow up. We look forward to reporting data from our ongoing Phase II study with CTX in disabled stroke patients in due course," said Chief Executive Olav Hellebø in a statement.
Shares in ReNeuron are trading up 3.5% at 3.75 pence Friday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)